Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Locally advanced esophageal adenocarcinoma remains difficult to treat and the ecological and evolutionary dynamics responsible for resistance and recurrence are incompletely understood. Here, we performed longitudinal multiomic analysis of patients with esophageal adenocarcinoma in the MEMORI trial. Multi-region multi-timepoint whole-exome and paired transcriptome sequencing was performed on 27 patients before, during and after neoadjuvant treatment. We found major transcriptomic changes during treatment with upregulation of immune, stromal and oncogenic pathways. Genetic data revealed that clonal sweeps through treatment were rare. Imaging mass cytometry and T cell receptor sequencing revealed remodeling of the tumor microenvironment during treatment. The presence of genetic immune escape, a less-cytotoxic T cell phenotype and a lack of clonal T cell expansions were linked to poor treatment response. In summary, there were widespread transcriptional and environmental changes through treatment, with limited clonal replacement, suggestive of phenotypic plasticity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122370PMC
http://dx.doi.org/10.1038/s43018-025-00955-wDOI Listing

Publication Analysis

Top Keywords

esophageal adenocarcinoma
12
neoadjuvant treatment
8
changes treatment
8
treatment
7
evolutionary immune
4
immune microenvironment
4
microenvironment dynamics
4
dynamics neoadjuvant
4
treatment esophageal
4
adenocarcinoma locally
4

Similar Publications

Single-cell analysis of Barrett's esophagus and carcinoma reveals cell types conferring risk via genetic predisposition.

Cell Genom

September 2025

Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. Electronic address:

Inherited genetic variants contribute to Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), but it is unknown which cell types are involved in this process. We performed single-cell RNA sequencing of BE, EAC, and paired normal tissues and integrated genome-wide association data to determine cell-type-specific genetic risk and cellular processes that contribute to BE and EAC. The analysis reveals that EAC development is driven to a greater extent by local cellular processes than BE development and suggests that one cell type of BE origin (intestinal metaplasia cells) and cellular processes that control the differentiation of columnar cells are of particular relevance for EAC development.

View Article and Find Full Text PDF

Background And Aims: Risk prediction models can identify individuals at high risk of esophageal adenocarcinoma. This systematic review aimed to critically appraise the available models for projecting absolute risk of esophageal adenocarcinoma in the general population.

Methods: We searched Medline, Embase, and Cochrane Library databases for studies of risk prediction models for esophageal adenocarcinoma.

View Article and Find Full Text PDF

Background: The incidence of esophageal adenocarcinoma (EA) has significantly increased in developed Western countries. Despite medical advancements, the prognosis remains poor, with a 5-year survival rate of less than 20%. By 2024, the global incidence is expected to reach 141,300 new cases annually, underscoring the urgent need to elucidate the mechanisms underlying EA pathogenesis to develop effective preventive and therapeutic strategies.

View Article and Find Full Text PDF

New Approaches to Screening for Barrett Esophagus.

Gastroenterol Hepatol (N Y)

June 2025

Division of Gastroenterology, Mayo Clinic, Jacksonville, Florida.

Current screening methods for Barrett esophagus (BE), the precursor to esophageal adenocarcinoma (EAC), are inadequate with less than one-third of screen-eligible patients currently undergoing screening. In addition to low screening rates, key issues include overemphasis on gastroesophageal reflux disease symptoms and lack of provider awareness, owing in part to heterogeneous guidelines. To address these challenges, several new approaches are being explored: swallowable cell collection devices, exhaled volatile organic compounds analysis, blood-based molecular biomarkers, microbiome analysis, and alternative visualization methods such as transnasal and capsule endos-copy.

View Article and Find Full Text PDF

Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.

Front Oncol

August 2025

Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, United States.

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the early detection of esophageal cancer (EC), offering a minimally invasive means to assess tumor-derived genomic and epigenomic alterations. This review synthesizes current data on ctDNA biology, detection technologies, diagnostic performance, and clinical applicability in both esophageal adenocarcinoma and squamous cell carcinoma. We conducted a comprehensive literature review of PubMed-indexed studies on ctDNA in EC, emphasizing recent (January 1, 2019- December 31, 2024) findings, systematic reviews, and meta-analyses.

View Article and Find Full Text PDF